Healthcare / BiotechnologyNasdaqCM
$0.43
-0.01 (-1.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.8M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
14.3x
↓EV/EBITDA
N/A
•ROE
-23.2%
↓Gross Margin
20.4%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-155.0%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.9M · net income $-18.0M · FCF $-4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.9M | $2.9M | $3.5M | — | — | — |
| Net Income | $-18.0M | $-18.0M | $-10.3M | $403780.00 | $1.1M | $-3308.00 |
| EBITDA | $-19.1M | $-19.1M | $-2.2M | $944591.00 | $1.1M | — |
| EPS | — | — | -0.54 | 0.19 | 0.49 | — |
| Gross Margin | 20.4% | 20.4% | 23.0% | — | — | — |
| Operating Margin | -631.0% | -631.0% | -331.2% | — | — | — |
| Net Margin | -619.8% | -619.8% | -292.6% | — | — | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.06 | 0.06 | 0.02 | 35.90 | 0.02 | — |
| Current Ratio | 0.16 | 0.16 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-4.5M | $-4.5M | $-1.8M | $-818766.00 | $-593703.18 | — |
| Returns | ||||||
| ROE | -23.2% | -23.2% | -7.2% | 1.2% | 1.1% | 156.0% |
| Valuation | ||||||
| P/E | 14.30 | 14.30 | — | 56.31 | — | — |
| EV/EBITDA | — | — | — | 1260.02 | — | — |
| P/B | 0.15 | 0.15 | 1.53 | 0.70 | — | — |
| Growth & Yield | ||||||
| Revenue Growth | -17.7% | -17.7% | — | — | — | — |
| EPS Growth | — | — | -386.0% | -62.1% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-70.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.54 → n/d
Residual
-70.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.